# A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction

> **NCT07091929** · PHASE1 · COMPLETED · sponsor: **Beijing Sungen Biomedical Technology Co., Ltd** · enrollment: 38 (actual)

## Conditions studied

- Anterior Myocardial Infarction

## Interventions

- **DRUG:** SGC001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07091929
- **Lead sponsor:** Beijing Sungen Biomedical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-20
- **Primary completion:** 2025-07-18
- **Final completion:** 2025-07-18
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07091929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07091929, "A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07091929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*